PAX5α enhances the epithelial behavior of human mammary carcinoma cells

Molecular Cancer Research

Volumn 8, Issue 3, 2010, Pages 444-456

  Vidal, Laurent J P ^a   Perry, Jo K ^a   Vouyovitch, Cecile M ^c,d   Pandey, Vijay ^a   Brunet Dunand, Severine E ^a   Mertani, Hichem C ^c,d   Liu, Dong Xu ^a   Lobie, Peter E ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c CENTRE LÉON BÉRARD   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; PROTEIN PAX5 ALPHA; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MESSENGER RNA; PAX5 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER INVASION; CELL COUNT; CELL MIGRATION; CELL MOTILITY; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; CARCINOMA; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL JUNCTION; CELL MOTION; CELL TRANSFORMATION; CYTOLOGY; DOWN REGULATION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MESODERM; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; ULTRASTRUCTURE;

B-CELL-SPECIFIC ACTIVATOR PROTEIN; BETA CATENIN; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CARCINOMA; CELL COUNT; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR JUNCTIONS; MESODERM; NEOPLASM INVASIVENESS; RNA INTERFERENCE; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 77949701835     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0368     Document Type: Article

References (69)

1. Samuel S, Naora H. Homeobox gene expression in cancer: insights from developmental regulation and deregulation. Eur J Cancer 2005; 41:2428-37.
2. Wang Q, FangWH, Krupinski J, Kumar S, Slevin M, Kumar P. Pax genes in embryogenesis and oncogenesis. J Cell Mol Med 2008;12:2281-94.
3. Treisman J, Harris E, Desplan C. The paired box encodes a second DNA-binding domain in the paired homeo domain protein. Genes Dev 1991;5:594-604.
4. Lang D, Powell SK, Plummer RS, Young KP, Ruggeri BA. PAX genes: roles in development, pathophysiology, and cancer. Biochem Pharmacol 2007;73:1-14.
5. Dahl E, Koseki H, Balling R. Pax genes and organogenesis. BioEssays 1997;19:755-65.
6. Robson EJ, He SJ, Eccles MR. A PANorama of PAX genes in cancer and development. Nat Rev Cancer 2006;6:52-62.
7. Barberis A, Widenhorn K, Vitelli L, Busslinger M. A novel B-cell lineage-specific transcription factor present at early but not late stages of differentiation. Genes Dev 1990;4:849-59.
8. Adams B, Dorfler P, Aguzzi A, et al. Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis. Genes Dev 1992;6:1589-607.
9. Torlakovic E, Slipicevic A, Robinson C, et al. Pax-5 expression in nonhematopoietic tissues. Am J Clin Pathol 2006;126:798-804.
10. Zwollo P, Arrieta H, Ede K, Molinder K, Desiderio S, Pollock R. The Pax-5 gene is alternatively spliced during B-cell development. J Biol Chem 1997;272:10160-8.
11. Busslinger M, Klix N, Pfeffer P, Graninger PG, Kozmik Z. Deregulation of PAX-5 by translocation of the Emu enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma. Proc Natl Acad Sci U S A 1996;93:6129-34.
12. Palmisano WA, Crume KP, Grimes MJ, et al. Aberrant promoter methylation of the transcription factor genes PAX5α and β in human cancers. Cancer Res 2003;63:4620-5.
13. Nutt SL, Thevenin C, Busslinger M. Essential functions of Pax-5 (BSAP) in pro-B cell development. Immunobiology 1997;198: 227-35.
14. Baumann Kubetzko FB, Di Paolo C, Maag C, et al. The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. Carcinogenesis 2004;25: 1839-46.
15. Kozmik Z, Sure U, Ruedi D, Busslinger M, Aguzzi A. Deregulated expression of PAX5 in medulloblastoma. Proc Natl Acad Sci U S A 1995;92:5709-13.
16. Stuart ET, Kioussi C, Aguzzi A, Gruss P. PAX5 expression correlates with increasing malignancy in human astrocytomas. Clin Cancer Res 1995;1:207-14.
17. Steinbach JP, Kozmik Z, Pfeffer P, Aguzzi A. Overexpression of Pax5 is not sufficient for neoplastic transformation of mouse neuroectoderm. Int J Cancer 2001;93:459-67.
18. Liu DX, Lobie PE. Transcriptional activation of p53 by Pitx1. Cell Death Differ 2007;14:1893-907.
19. Mertani HC, Zhu T, Goh EL, Lee KO, Morel G, Lobie PE. Autocrine human growth hormone (hGH) regulation of human mammary carcinoma cell gene expression. Identification of CHOP as a mediator of hGH-stimulated human mammary carcinoma cell survival. J Biol Chem 2001;276:21464-75.
20. Araneda S, Pelloux S, Radicella JP, et al. 8-Oxoguanine DNA glycosylase, but not Kin17 protein, is translocated and differentially regulated by estrogens in rat brain cells. Neuroscience 2005;136: 135-46.
21. Mertani HC, Garcia-Caballero T, Lambert A, et al. Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int J Cancer 1998;79:202-11.
22. Mukhina S, Mertani HC, Guo K, Lee KO, Gluckman PD, Lobie PE. Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proc Natl Acad Sci U S A 2004;101: 15166-71.
23. Kaulsay KK, Zhu T, Bennett W, Lee KO, Lobie PE. The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology 2001;142:767-77.
24. Zhang X, Zhu T, Chen Y, Mertani HC, Lee KO, Lobie PE. Human growth hormone-regulated HOXA1 is a human mammary epithelial oncogene. J Biol Chem 2003;278:7580-90.
25. Zhu T, Starling-Emerald B, Zhang X, et al. Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer Res 2005;65:317-24.
26. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-72.
27. Loi S, Haibe-Kains B, Desmedt C, et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008;9:239.
28. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006;24:4236-44.
29. Huang E, Cheng SH, Dressman H, et al. Gene expression predictors of breast cancer outcomes. Lancet 2003;361:1590-6.
30. Desmedt C, Piette F, Loi S, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007;13:3207-14.
31. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007;25:1239-46.
32. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009.
33. Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat 2008;108:191-201.
34. West M, Blanchette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A 2001;98:11462-7.
35. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-9.
36. Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cell Biol 1992;12:2662-72.
37. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
38. Stuart ET, Haffner R, Oren M, Gruss P. Loss of p53 function through PAX-mediated transcriptional repression. EMBO J 1995;14:5638-45.
39. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
40. Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 1994;31:325-35.
41. Baum B, Settleman J, Quinlan MP. Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 2008;19:294-308.
42. Wells A, Yates C, Shepard CR. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis 2008;25:621-8.
43. ChafferCL, Thompson EW,Williams ED.Mesenchymal to epithelial transition in development and disease.Cells TissuesOrgans 2007;185:7-19.
44. Hartsock A, Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta 2008;1778:660-9.
45. Holmes ML, Pridans C, Nutt SL. The regulation of the B-cell gene expression programme by Pax5. Immunol Cell Biol 2008;86:47-53.
46. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol 2007;8:463-70.
47. Mayes DA, Hu Y, Teng Y, et al. PAX6 suppresses the invasiveness of glioblastoma cells and the expression of the matrix metalloproteinase-2 gene. Cancer Res 2006;66:9809-17.
48. Hugo H, Ackland ML, Blick T, et al. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 2007;213:374-83.
49. Bouchard M, Souabni A, Mandler M, Neubuser A, Busslinger M. Nephric lineage specification by Pax2 and Pax8. Genes Dev 2002; 16:2958-70.
50. Wiggan O, Hamel PA. Pax3 regulates morphogenetic cell behavior in vitro coincident with activation of a PCP/non-canonical Wntsignaling cascade. J Cell Sci 2002;115:531-41.
51. Ellsworth RE, Seebach J, Field LA, et al. A gene expression signature that defines breast cancer metastases. Clin Exp Metastasis 2009;26: 205-13.
52. Mhawech-Fauceglia P, Saxena R, Zhang S, et al. Pax-5 immunoexpression in various types of benign and malignant tumours: a highthroughput tissue microarray analysis. J Clin Pathol 2007;60:709-14.
53. Sherr CJ. Principles of tumor suppression. Cell 2004;116:235-46.
54. Silberstein GB, Dressler GR, Van Horn K. Expression of the PAX2 oncogene in human breast cancer and its role in progesteronedependent mammary growth. Oncogene 2002;21:1009-16.
55. Hurtado A, Holmes KA, Geistlinger TR, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008;456:663-6.
56. Wu H, Chen Y, Liang J, et al. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 2005;438:981-7.
57. Vouyovitch CM, Vidal L, Borges S, et al. Proteomic analysis of autocrine/ paracrine effects of human growth hormone in human mammary carcinoma cells. Adv Exp Med Biol 2008;617:493-500.
58. Moggs JG, Orphanides G. Estrogen receptors: orchestrators of pleiotropic cellular responses. EMBO Rep 2001;2:775-81.
59. Perry JK, Emerald BS, Mertani HC, Lobie PE. The oncogenic potential of growth hormone. Growth Horm IGF Res 2006;16:277-89.
60. Michaelson JS, Leder P. β-Catenin is a downstream effector of Wntmediated tumorigenesis in the mammary gland. Oncogene 2001;20: 5093-9.
61. Imbert A, Eelkema R, Jordan S, Feiner H, Cowin P. ΔN89 β-catenin induces precocious development, differentiation, and neoplasia in mammary gland. J Cell Biol 2001;153:555-68.
62. Brennan KR, Brown AM. Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia 2004;9:119-31.
63. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51.
64. Baba Y, Garrett KP, Kincade PW. Constitutively active β-catenin confers multilineage differentiation potential on lymphoid and myeloid progenitors. Immunity 2005;23:599-609.
65. Na YR, Seok SH, Kim DJ, et al. Bone morphogenetic protein 7 induces mesenchymal-to-epithelial transition in melanoma cells, leading to inhibition of metastasis. Cancer Sci 2009;100:2218-25.
66. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007;8:341-52.
67. Balasenthil S, Gururaj AE, Talukder AH, et al. Identification of Pax5 as a target of MTA1 in B-cell lymphomas. Cancer Res 2007; 67:7132-8.
68. Nutt SL, Morrison AM, Dorfler P, Rolink A, Busslinger M. Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. EMBO J 1998;17: 2319-33.
69. Norhany S, Kouzu Y, Uzawa K, et al. Overexpression of PAX5 in oral carcinogenesis. Oncol Rep 2006;16:1003-8.